B. Riley analyst Anderson Schock downgraded ZimVie (ZIMV) to Neutral from Buy with a price target of $19, up from $16, after the company entered into a definitive agreement to be acquired by Archimed for $19 per share in cash. While the 40 day go-shop period creates potential for superior offers, the closing of the Archimed deal is the most probable outcome, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV:
- ZimVie Inc. Reports Q2 2025 Results Amid Acquisition
- ZimVie withdraws guidance amid ARCHIMED transaction
- ZimVie will not host withdraws guidance amid ARCHIMED transaction
- ZimVie announces exclusive distribution agreement with Osstem Implant in China
- ZimVie upgraded to Equal Weight from Underweight at Barclays